BF
ALXN

BOK Financial’s Alexion Pharmaceuticals ALXN Stock Holding History

BOK Financial’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-9,053
Closed -$1.41M – 959
2020
Q4 		$1.41M Sell
9,053
-6,134
-40% -$788K 0.03% 439
2020
Q3 		$1.74M Buy
15,187
+7,630
+101% +$823K 0.04% 349
2020
Q2 		$848K Buy
+7,557
New +$802K 0.02% 499
2019
Q3 		– Sell
-2,037
Closed -$266K – 957
2019
Q2 		$266K Buy
+2,037
New +$263K 0.01% 799
2019
Q1 		– Sell
-4,630
Closed -$450K – 942
2018
Q4 		$450K Buy
4,630
+536
+13% +$63.4K 0.01% 645
2018
Q3 		$569K Sell
4,094
-2,157
-35% -$271K 0.01% 647
2018
Q2 		$776K Buy
6,251
+3,861
+162% +$451K 0.02% 543
2018
Q1 		$266K Sell
2,390
-524
-18% -$62.6K 0.01% 804
2017
Q4 		$349K Sell
2,914
-1,542
-35% -$188K 0.01% 758
2017
Q3 		$626K Buy
4,456
+540
+14% +$73.4K 0.02% 605
2017
Q2 		$476K Sell
3,916
-2,320
-37% -$270K 0.02% 644
2017
Q1 		$756K Sell
6,236
-655
-10% -$84.4K 0.02% 550
2016
Q4 		$843K Sell
6,891
-95
-1% -$11.6K 0.03% 504
2016
Q3 		$856K Buy
6,986
+439
+7% +$56.5K 0.03% 507
2016
Q2 		$764K Buy
6,547
+861
+15% +$122K 0.03% 498
2016
Q1 		$791K Sell
5,686
-22,181
-80% -$3.26M 0.03% 479
2015
Q4 		$5.32M Sell
27,867
-12,058
-30% -$2.11M 0.19% 128
2015
Q3 		$6.24M Sell
39,925
-2,591
-6% -$473K 0.24% 96
2015
Q2 		$7.69M Sell
42,516
-23,579
-36% -$4.07M 0.26% 90
2015
Q1 		$11.5M Buy
66,095
+1,861
+3% +$337K 0.39% 58
2014
Q4 		$11.9M Buy
64,234
+10,015
+18% +$1.86M 0.41% 54
2014
Q3 		$8.99M Buy
54,219
+32,430
+149% +$5.33M 0.3% 73
2014
Q2 		$3.4M Sell
21,789
-2,762
-11% -$436K 0.11% 207
2014
Q1 		$3.73M Sell
24,551
-1,376
-5% -$219K 0.12% 186
2013
Q4 		$3.45M Sell
25,927
-3,260
-11% -$391K 0.12% 199
2013
Q3 		$3.39M Sell
29,187
-4,880
-14% -$535K 0.12% 181
2013
Q2 		$3.14M Buy
+34,067
New +$3.28M 0.12% 179

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BOK Financial's ALXN Position: Q1 2021 in Review

BOK Financial sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 9,053 shares — an estimated $1.41M sold.

BOK Financial first reported a position in ALXN in Q2 2013 and held it in 27 quarters. The position peaked at $11.9M in Q4 2014. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • BOK Financial reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • BOK Financial sold 9,053 Alexion Pharmaceuticals shares in Q1 2021, an estimated $1.41M.
  • BOK Financial first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
  • BOK Financial's Alexion Pharmaceuticals position peaked at $11.9M in Q4 2014.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on BOK Financial's 13F filing for Q1 2021, filed 21 Apr 2021.